2022
Can We Utilize PROMIS Neuropathic Pain Quality for Assessment of Neuropathic Heel Pain?
Joo P, Hoffman S, Baumhauer J, Oh I. Can We Utilize PROMIS Neuropathic Pain Quality for Assessment of Neuropathic Heel Pain? Foot & Ankle Orthopaedics 2022, 7: 2473011421s00713. PMCID: PMC9666847, DOI: 10.1177/2473011421s00713.Peer-Reviewed Original ResearchBody mass indexBack/neck painNeuropathic painSevere neuropathic painHeel painNeuropathic pain qualitiesPhysical functionPain interferenceT-scoreNeck painPain qualityOnly significant independent factorTertiary care academic institutionLow physical functionOutcomes Measurement Information SystemSignificant independent factorsMeasurement Information SystemNeuropathic mechanismsCurrent smokersMost etiologiesNociceptive painSecondary outcomesCommon presentationInitial visitPain management
2008
Clinically Tolerated Strategies for NMDA Receptor Antagonism
Vincent Chen H, Zhang D, Lipton S. Clinically Tolerated Strategies for NMDA Receptor Antagonism. The Receptors 2008, 327-361. DOI: 10.1007/978-1-59745-055-3_8.Peer-Reviewed Original ResearchExcessive NMDAR activityNMDAR activityClinical trialsGlutamate receptorsSide effectsNeurologic disordersNervous systemAcute hypoxic-ischemic brain injuryGeneralized inhibitionAlzheimer's diseaseSecond-generation memantine derivativesHypoxic-ischemic brain injuryPhase 3 clinical trialsExcessive NMDAR activationSevere neuropathic painExcitatory amino acidsGlutamate-mediated neurotoxicityGlutamate receptor subtypesChronic neurodegenerative diseasesSystemic side effectsMajor excitatory transmitterNormal functionNMDA receptor antagonismGreater neuroprotective propertiesCentral nervous system
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply